Original Article
Brief Report
Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients
N Engl J Med 2008; 358:811-817February 21, 2008
- Abstract
Hepatitis E virus (HEV) is considered an agent responsible for acute hepatitis that does not progress to chronic hepatitis. We identified 14 cases of acute HEV infection in three patients receiving liver transplants, nine receiving kidney transplants, and two receiving kidney and pancreas transplants. All patients were positive for serum HEV RNA. Chronic hepatitis developed in eight patients, as confirmed by persistently elevated aminotransferase levels, serum HEV RNA, and histologic features of chronic hepatitis. The time from transplantation to diagnosis was significantly shorter and the total counts of lymphocytes and of CD2, CD3, and CD4 T cells were significantly lower in patients in whom chronic disease developed.
Media in This Article
Table 1
Demographic Features of Transplant Recipients at Diagnosis of Acute HEV Infection.Table 2
Liver Function in Patients with HEV Infection.Article Activity
- Article
Acute hepatitis caused by the hepatitis E virus (HEV) is endemic in developing countries and appears to be an emerging disease in industrialized countries.1,2 Seroprevalence studies have reported anti-HEV IgG antibodies in 6 to 16% of renal-transplant recipients.3,4 This hepatotropic RNA virus is often not fully considered or routinely sought in cases of acute hepatitis in recipients of solid-organ transplants. Only three cases of acute HEV infection have been reported in organ-transplant recipients.5-7 Even though two cases of persistent HEV infection have been reported,8,9 HEV is considered an agent responsible for acute hepatitis that does not become chronic.10
We report here 14 cases of acute hepatitis E infection in organ-transplant recipients. We suggest that HEV infection may evolve to chronic hepatitis in immunocompromised patients.
Patients and Methods
Between January 1, 2004, and December 31, 2006, all recipients of liver, kidney, or kidney and pancreas transplants attending our outpatient and inpatient clinics who presented with unexplained short-term elevations of liver-enzyme levels were screened for HEV infection by serologic and molecular tools. Patients chronically infected with hepatitis B, C, or D viruses were excluded from the study. Biliary-tract complications were ruled out by abdominal ultrasonography. Toxin- and drug-related causes of abnormal liver-function test results were ruled out by patient history. Fourteen of 217 patients (6.5%) tested positive for serum HEV RNA.
Anti-HEV status was determined by an enzyme immunoassay (HEV EIA, Abbott). HEV RNA in serum and stool was detected by real-time polymerase-chain-reaction (PCR) amplification (TaqMan, Applied Biosystems) of a 189-bp product located in the ORF2 region.11 Strains were sequenced and compared with reference HEV strains (GenBank). The grades and stages of chronic hepatitis were assessed according to the Metavir classification.12
Proportions were compared by the chi-square test or Fisher's exact test. Quantitative variables were compared by the nonparametric Mann–Whitney, Friedman, and Wilcoxon tests. A P value of less than 0.05 was considered to indicate statistical significance.
Results
Prevalence of Anti-HEV IgG
All patients who received a kidney transplant (241 recipients) or a liver transplant (86 recipients) between January 1, 2004, and December 31, 2006, in the department of nephrology, dialysis, and multiorgan transplantation were screened for HEV infection at the time of transplantation. The prevalence of anti-HEV IgG was 13.5% for all recipients, 14.5% for kidney recipients, and 10.4% for liver recipients.
Clinical and Biologic Presentation
We identified 14 patients with a solid-organ transplant (3 liver recipients, 9 kidney recipients, and 2 kidney and pancreas recipients) in whom acute HEV infection developed (Table 1Table 1
Demographic Features of Transplant Recipients at Diagnosis of Acute HEV Infection.). The acute hepatitis episode was asymptomatic in 7 of the 14 patients; these 7 patients were tested for HEV after liver-enzyme abnormalities were detected during routine biologic examinations that are performed every 3 to 4 months after organ transplantation. The seven other patients presented with fatigue, diffuse arthralgias, and myalgias that had evolved over a period of 1 to 2 weeks. One of the symptomatic patients also had marked weight loss (approximately 8 kg [18 lb] during the month before the presenting symptoms appeared) and was icteric. The symptoms disappeared within 2 weeks after diagnosis. No abnormalities were detected during physical examination of any other patient. No patients were febrile, and none had traveled outside France during the year before their hepatitis episode. Only two patients reported having been in contact with animals: one patient with chickens and rabbits and the other with birds. No patients had had an acute rejection episode after undergoing transplantation. Immunosuppressive therapy had remained unchanged in all patients for at least 6 months before their acute episode. Liver-enzyme levels were significantly higher than the levels 3 to 4 months before the diagnosis of HEV infection (Table 2Table 2Liver Function in Patients with HEV Infection.).Diagnosis of HEV Infection
At admission, classic causes of hepatitis were ruled out (Table 1 of the Supplementary Appendix, available with the full text of this article at www.nejm.org). The ferritin level was 567 ng per milliliter (range, 110 to 2007; normal range, 30 to 380), and the ceruloplasmin level was 0.35 ng per milliliter (range, 0.24 to 0.47; normal range, 0.20 to 0.45). At diagnosis, HEV RNA was detected in the serum of all patients and in the stool of the three patients whose stool was examined. PCR-amplification products of the serum HEV of 12 patients were sequenced and analyzed. Phylogenetic analysis revealed that all the strains belonged to genotype 3 (GenBank accession numbers, EU220992 to EU221003) (Fig. 1 of the Supplementary Appendix). We tried but failed to sequence the strains of the remaining two patients. No correlation was found between HEV RNA concentration and either liver-enzyme levels or liver-activity scores at diagnosis.
Liver Histologic Findings during the Acute Phase
In the acute phase, 9 of the 14 patients underwent a liver biopsy to evaluate the severity of the acute episode of hepatitis; the remaining 5 patients declined biopsy. In liver-transplant recipients, liver biopsy also was performed to detect acute rejection. The mean (±SD) Metavir activity and fibrosis scores were 1.3±1.0 and 0.9±0.6, respectively (for assessment of disease activity, a Metavir score of 0 indicates no activity, 1 mild activity, 2 moderate activity, and 3 severe activity; for assessment of fibrosis, a Metavir score of 0 indicates no fibrosis, 1 portal fibrosis without septa, 2 a few septa, 3 numerous septa without cirrhosis, and 4 cirrhosis). The dominant lesions were lobular, with inflammation but no ballooning, and with spotty necrosis that included acidophilic bodies. The portal tract was mildly or moderately expanded and included an inflammatory infiltrate composed mainly of lymphocytes. Mild piecemeal necrosis was observed in six patients.
Course of HEV Infection
Immunosuppressive therapy and target immunosuppressive trough levels were not modified after the diagnosis of HEV infection (data not shown). HEV infection resolved in six patients (43%); serum and stool HEV RNA in these patients became undetectable within 6 months after diagnosis and remained undetectable until the last follow-up at a mean of 12 months (range, 5 to 36) (Table 2). However, in the eight other patients (57%), HEV infection evolved to chronic hepatitis, as indicated by persistently elevated liver-enzyme levels and detectable HEV RNA in the serum or stool for a mean of 15 months (range, 10 to 24) after the acute phase.
Among the patients with resolving HEV infection, the levels of aspartate aminotransferase and alanine aminotransferase returned to preinfection values within 1 month (five patients) or 3 months (one patient) after diagnosis. The levels of γ-glutamyltransferase and alkaline phosphate returned to baseline levels within 3 months after diagnosis. Among those with chronic HEV infection, liver-enzyme levels remained above the upper limit of normal at the last follow-up. In both groups, the total bilirubin levels rapidly returned to preinfection levels. In both groups, hematologic and renal measurements remained unchanged during the follow-up as compared with preinfection levels (data not shown). HEV seroconversion was observed in four patients with resolving HEV infection (two at 1 month and one each at 3 and 6 months after diagnosis) and seven patients with chronic infection (one at 3 months, two at 6 months, two at 12 months, and one each at 13 and 15 months after diagnosis).
Only six of the eight patients with chronic infection underwent a second liver biopsy (one at 10 months, two at 12 months, and one each at 13, 15, and 18 months after the diagnosis of acute HEV infection). The two remaining patients declined liver biopsy. The mean Metavir activity and fibrosis scores of the six patients who underwent biopsy were 2.0±1.0 and 1.8±0.8, respectively. All biopsy specimens showed features of chronic viral hepatitis, characterized by fibrosis and portal hepatitis, with dense lymphocytic infiltrate and variable degrees of piecemeal necrosis. Lobular hepatitis was mild to moderate in all cases. In the four patients who underwent a liver biopsy during both the acute phase and the chronic phase, the Metavir activity scores progressed from 1.0±0.8 to 2.2±0.9 and the fibrosis scores from 1.2±0.5 to 1.5±0.5.
Resolving versus Chronic HEV Infection
During the acute phase, there were no significant differences between the patients with resolving HEV infection and those with chronic infection in median serum HEV RNA concentrations (5.97 log10 copies of RNA per milliliter [range, 5.79 to 6.44] and 6.18 log10 copies per milliliter [range, 4.92 to 7.28], respectively). There also were no significant differences between the groups in peak liver-enzyme levels. Hepatitis developed later after transplantation in patients with resolving HEV infection than in those in whom the infection progressed. Patients in whom chronic hepatitis developed had significantly lower serum creatinine levels at baseline and significantly lower counts of leukocytes, total lymphocytes, platelets, and CD2, CD3, and CD4 lymphocytes (Table 3Table 3
Patients with Resolving HEV Infection and Those in Whom the Infection Evolved to Chronic Hepatitis.). The percentages of patients who received induction therapy at transplantation or who received calcineurin inhibitors, mycophenolate mofetil or sodium, or inhibitors of the mammalian target of rapamycin (mTOR) were similar in the two groups. The dosage and trough levels of immunosuppressive drugs, as well as the proportions of patients with anti–hepatitis A virus, anticytomegalovirus, or IgG antibodies to Epstein–Barr virus, were similar in the two groups (data not shown).Discussion
HEV infection is transmitted by the fecal–oral route and may be a zoonosis in industrialized countries. It has a mortality rate of about 1% in the general population and 30% in pregnant women.13 HEV-induced acute hepatitis may be fulminant,14 but we are not aware that any cases of chronic hepatitis have previously been reported. Recently, the diagnosis of many cases of acute HEV hepatitis in nonimmunocompromised patients in southwest France15 prompted us to look systematically for HEV in recipients of solid-organ transplants who had unexplained hepatitis. Of the 14 patients with acute HEV infection whom we report on here, 8 underwent progression to chronic hepatitis. In addition, in this issue of the Journal, Gérolami et al. report a case of HEV-related cirrhosis in a kidney-transplant recipient.16
After all other causes of hepatitis had been ruled out, the serum of 14 patients, none of whom had traveled outside France in the previous year, was found to be positive for HEV RNA. We did not identify any source of contamination. The peak aminotransferase levels were lower than in nonimmunocompromised patients.17,18 Histologic lesions (mainly spotty lobular necrosis) that are characteristic of classic acute viral hepatitis were seen; these lesions were less severe than those typically seen in nonimmunocompromised patients. These findings could be related to the immunosuppressive therapy in transplant recipients.
HEV infection resolved in 6 of the 14 patients within 6 months after the end of the acute phase. In contrast, HEV infection in eight patients evolved to chronic hepatitis, as indicated by persistently elevated liver-enzyme levels and detectable serum HEV RNA at a median of 15 months (range, 10 to 24) after the end of the acute phase. Liver biopsies performed at a median of 12.5 months (range, 10 to 18) after the acute phase revealed signs of chronic viral hepatitis. The histologic lesions — dense lymphocytic portal infiltrate with constant piecemeal necrosis — were similar to those observed in patients chronically infected with hepatitis C virus. None of the patients received any specific therapy; in particular, none received antiviral therapy. Immunosuppressive therapy was not modified after the diagnosis of HEV. In the absence of available therapeutic recommendations for patients infected with HEV, we only performed close monitoring of liver-enzyme levels.
There were no significant differences between patients with resolving HEV infection and those with chronic HEV infection in demographic or clinical features, including treatment with immunosuppressive agents before the acute phase. However, the immunologic status of the patients may have had a role in the evolution to chronic disease. In patients in whom the infection became chronic, the time from transplantation to the development of infection was significantly shorter — and consequently, the total lymphocyte counts and the CD2, CD3, and CD4 lymphocyte counts were significantly lower — than in patients in whom HEV infection resolved. Hence, the T-cell response seems to have a role in HEV clearance, as does the B-cell response.
HEV seroconversion occurred later in patients with chronic infection than in those with resolving infection. This difference may be related to the reduction in the humoral immune response caused by treatment with mycophenolate, inhibitors of mTOR, or both. These drugs are known to decrease the synthesis of antibodies19,20 and to inhibit the cell-cycle progression and differentiation of human B lymphocytes.21 The humoral immune response is necessary to clear HEV and to prevent hepatitis. Bryan et al. have shown that antibodies to the HEV capsid can be protective against hepatitis E.22 Passive immunoprophylaxis studies in cynomolgus monkeys have confirmed that the antibody to the HEV capsid may prevent HEV infection in humans.23 Recently an HEV recombinant protein vaccine was found to be effective in preventing HEV infection.24
Further studies are required to determine the incidence of chronic HEV infection in transplant recipients who live in areas where the disease is not endemic. Vaccination against HEV could be proposed to patients before or after organ transplantation. However, the efficacy of vaccination in these populations should be addressed.
In conclusion, our data suggest that HEV should be considered an etiologic agent of hepatitis in organ-transplant recipients. We have demonstrated that HEV infection can evolve to chronic hepatitis, at least in organ-transplant recipients. A longer follow-up is required to assess the outcome of HEV infection in organ-transplant recipients.
No potential conflict of interest relevant to this article was reported.
We thank Mrs. Martine Dubois for her technical assistance.
Source Information
From the Department of Nephrology, Dialysis, and Multiorgan Transplantation (N.K., L.O., J.G., O.C., L.E., D.D., L.R.) and INSERM Unité 858, IFR 31 (N.K., J.-M.P.), Centre Hospitalier Universitaire, Rangueil, France; and the Departments of Histopathology (J.S., M.D.), Virology (J.-M.M., F.A., J.I.), and Hepatology (J.-M.P., J.-P.V.), and INSERM Unité 563, IFR 30 (F.A., J.I., L.R.), Centre Hospitalier Universitaire, Purpan — all in Toulouse, France.
Address reprint requests to Dr. Kamar at the Department of Nephrology, Dialysis, and Multiorgan Transplantation, CHU Rangueil, TSA 50032, 31059 Toulouse CEDEX 9, France, or at kamar.n@chu-toulouse.fr.
- References
References
1
Clemente-Casares P ,Pina S ,Buti M , et al. Hepatitis E virus epidemiology in industrialized countries. Emerg Infect Dis 2003;9:448-454
Web of Science | Medline2
Meng XJ ,Wiseman B ,Elvinger F , et al. Prevalence of antibodies to hepatitis E virus in veterinarians working with swine and in normal blood donors in the United States and other countries. J Clin Microbiol 2002;40:117-122
CrossRef | Web of Science | Medline3
Ibarra H ,Riedemann S ,Reinhardt G ,Ardiles L ,Calvo M ,Siegel F . Anti-HEV in dialysis and renal transplant patients in an endemic region in Chile. Clin Nephrol 1998;50:267-268
Web of Science | Medline4
Buffet C ,Laurent-Puig P ,Chandot S , et al. A high hepatitis E virus seroprevalence among renal transplantation and haemophilia patient populations. J Hepatol 1996;24:122-125
CrossRef | Web of Science | Medline5
Sinha S ,Jha R ,Lakhtakia S ,Narayan G . Acute pancreatitis following kidney transplantation -- role of viral infections. Clin Transplant 2003;17:32-36
CrossRef | Web of Science | Medline6
Kamar N ,Mansuy JM ,Esposito L , et al. Acute hepatitis and renal function impairment related to infection by hepatitis E virus in a renal-allograft recipient. Am J Kidney Dis 2005;45:193-196
CrossRef | Web of Science | Medline7
Peron JM ,Mansuy JM ,Recher C , et al. Prolonged hepatitis E in an immunocompromised patient. J Gastroenterol Hepatol 2006;21:1223-1224
CrossRef | Web of Science | Medline8
Mechnik L ,Bergman N ,Attali M , et al. Acute hepatitis E virus infection presenting as a prolonged cholestatic jaundice. J Clin Gastroenterol 2001;33:421-422
CrossRef | Web of Science | Medline9
Tamura A ,Shimizu YK ,Tanaka T , et al. Persistent infection of hepatitis E virus transmitted by blood transfusion in a patient with T-cell lymphoma. Hepatol Res 2007;37:113-120
CrossRef | Web of Science | Medline10
Emerson SU ,Purcell RH . Hepatitis E virus. Rev Med Virol 2003;13:145-154
CrossRef | Web of Science | Medline11
Mansuy JM ,Peron JM ,Bureau C ,Alric L ,Vinel JP ,Izopet J . Immunologically silent autochthonous acute hepatitis E virus infection in France. J Clin Microbiol 2004;42:912-913
CrossRef | Web of Science | Medline12
Bedossa P ,Poynard T . An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996;24:289-293
CrossRef | Web of Science | Medline13
Kumar A ,Beniwal M ,Kar P ,Sharma JB ,Murthy NS . Hepatitis E in pregnancy. Int J Gynaecol Obstet 2004;85:240-244
CrossRef | Web of Science | Medline14
Peron JM ,Bureau C ,Poirson H , et al. Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy. J Viral Hepat 2007;14:298-303
CrossRef | Web of Science | Medline15
Mansuy JM ,Peron JM ,Abravanel F , et al. Hepatitis E in the south west of France in individuals who have never visited an endemic area. J Med Virol 2004;74:419-424
CrossRef | Web of Science | Medline16
Gérolami R, Moal V, Colson P. Chronic hepatitis E with cirrhosis in a kidney-transplant recipient. N Engl J Med 2008;859-60.
17
Peron JM ,Mansuy JM ,Poirson H , et al. Hepatitis E is an autochthonous disease in industrialized countries: analysis of 23 patients in South-West France over a 13-month period and comparison with hepatitis A. Gastroenterol Clin Biol 2006;30:757-762
CrossRef | Medline18
Peron JM ,Danjoux M ,Kamar N , et al. Liver histology in patients with sporadic acute hepatitis E: a study of 11 patients from South-West France. Virchows Arch 2007;450:405-410
CrossRef | Web of Science | Medline19
Rentenaar RJ ,van Diepen FN ,Meijer RT , et al. Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo. Kidney Int 2002;62:319-328
CrossRef | Web of Science | Medline20
Luo H ,Chen H ,Daloze P ,Chang JY ,St-Louis G ,Wu J . Inhibition of in vitro immunoglobulin production by rapamycin. Transplantation 1992;53:1071-1076
CrossRef | Web of Science | Medline21
Aagaard-Tillery KM ,Jelinek DF . Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell Immunol 1994;156:493-507
CrossRef | Web of Science | Medline22
Bryan JP ,Tsarev SA ,Iqbal M , et al. Epidemic hepatitis E in Pakistan: patterns of serologic response and evidence that the antibody to hepatitis E virus protects against disease. J Infect Dis 1994;170:517-521
CrossRef | Web of Science | Medline23
Tsarev SA ,Tsareva TS ,Emerson SU , et al. Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proc Natl Acad Sci U S A 1994;91:10198-10202
CrossRef | Web of Science | Medline24
Shrestha MP ,Scott RM ,Joshi DM , et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007;356:895-903
Full Text | Web of Science | Medline
- Citing Articles (128)
Citing Articles
1
N.F. Crum-Cianflone, . (2012) Hepatitis E Virus Infection in HIV-infected Persons. Emerging Infectious Diseases 18:3,
CrossRef2
P. Gupta, N. Jagya, S. B. Pabhu, H. Durgapal, S. K. Acharya, S. K. Panda. (2012) Immunohistochemistry for the diagnosis of hepatitis E virus infection. Journal of Viral Hepatitis 19:2, e177-e183
CrossRef3
Anne Motte, Bertrand Roquelaure, Claire Galambrun, Fanette Bernard, Christine Zandotti, Philippe Colson. (2012) Hepatitis E in three immunocompromized children in southeastern France. Journal of Clinical Virology 53:2, 162-166
CrossRef4
R Jardi, M Crespo, M Homs, E Eyden, R Girones, J Rodriguez-, A Caballero, M Buti, R Esteban, F Rodriguez-Frias. (2012) HIV, HEV and cirrhosis: evidence of a possible link from eastern Spain. HIV Medicinen/a-n/a
CrossRef5
B. Schlosser, A. Stein, R. Neuhaus, S. Pahl, B. Ramez, D.H. Krüger, T. Berg, J. Hofmann. (2012) Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient. Journal of Hepatology 56:2, 500-502
CrossRef6
Sarah Maylin, Robin Stephan, Jean-Michel Molina, Marie-Noelle Peraldi, Catherine Scieux, Elisabeth Nicand, François Simon, Constance Delaugerre. (2012) Prevalence of antibodies and RNA genome of hepatitis E virus in a cohort of French immunocompromised. Journal of Clinical Virology
CrossRef7
Stefan G. Hübscher, Andrew D. Clouston. 2012. Transplantation pathology. , 853-933.
CrossRef8
Neil D. Theise, Henry C. Bodenheimer, Linda D. Ferrell. 2012. Acute and chronic viral hepatitis. , 361-401.
CrossRef9
S.K. Sarin, Manoj Kumar. 2012. Hepatitis E. , 605-628.
CrossRef10
Andreas Osterman, Maria Guadalupe Vizoso Pinto, Rudolf Haase, Hans Nitschko, Simone Jaeger, Michaela Sander, Manfred Motz, Ulrich Mohn, Armin Baiker. (2012) Systematic screening for novel, serologically reactive Hepatitis E Virus epitopes. Virology Journal 9:1, 28
CrossRef11
Joshua Watson, Maria H. Sjogren. 2011. Hepatitis A and E. , 521-536.
CrossRef12
K. Matsubayashi, H. Sakata, H. Ikeda. (2011) Hepatitis E virus infection and blood transfusion in Japan. ISBT Science Series 6:2, 344-349
CrossRef13
Tatsunori Nakano, Kazuaki Takahashi, Oliver G. Pybus, Naoaki Hashimoto, Hideaki Kato, Hiroshi Okano, Makoto Kobayashi, Naoki Fujita, Katsuya Shiraki, Yoshiyuki Takei, Minoru Ayada, Masahiro Arai, Hiroaki Okamoto, Shunji Mishiro. (2011) New findings regarding the epidemic history and population dynamics of Japan-indigenous genotype 3 hepatitis E virus inferred by molecular evolution. Liver Internationaln/a-n/a
CrossRef14
Irene Cacciola, Federica Messineo, Bruno Cacopardo, Vito Di Marco, Claudio Galli, Giovanni Squadrito, Cristina Musolino, Carlo Saitta, Teresa Pollicino, Giovanni Raimondo. (2011) Hepatitis E virus infection as a cause of acute hepatitis in Southern Italy. Digestive and Liver Disease 43:12, 996-1000
CrossRef15
Raymund R. Razonable. (2011) Rare, unusual, and less common virus infections after organ transplantation. Current Opinion in Organ Transplantation 16:6, 580-587
CrossRef16
Kenrad E Nelson, Brittany Kmush, Alain B Labrique. (2011) The epidemiology of hepatitis E virus infections in developed countries and among immunocompromised patients. Expert Review of Anti-infective Therapy 9:12, 1133-1148
CrossRef17
Rakesh Aggarwal, Shahid Jameel. (2011) Hepatitis E. Hepatology 54:6, 2218-2226
CrossRef18
Gurmit K. Jagjit Singh, Samreen Ijaz, Neesha Rockwood, Simon P. Farnworth, Emma Devitt, Mark Atkins, Richard Tedder, Mark Nelson. (2011) Chronic Hepatitis E as a cause for cryptogenic cirrhosis in HIV. Journal of Infection
CrossRef19
C. Koenecke, S. Pischke, A. Heim, L. Raggub, B. Bremer, R. Raupach, S. Buchholz, T. Schulz, M.P. Manns, A. Ganser, H. Wedemeyer. (2011) Chronic hepatitis E in hematopoietic stem cell transplant patients in a low-endemic country?. Transplant Infectious Diseasen/a-n/a
CrossRef20
Hideyuki Takahashi, Toshinori Tanaka, Suljid Jirintai, Shigeo Nagashima, Masaharu Takahashi, Tsutomu Nishizawa, Hitoshi Mizuo, Yasuyuki Yazaki, Hiroaki Okamoto. (2011) A549 and PLC/PRF/5 cells can support the efficient propagation of swine and wild boar hepatitis E virus (HEV) strains: demonstration of HEV infectivity of porcine liver sold as food. Archives of Virology
CrossRef21
Harry R. Dalton, Richard P. Bendall, Mo Rashid, Vic Ellis, Rachel Ali, Rene Ramnarace, William Stableforth, William Headdon, Rose Abbott, Cara McLaughlin, Emma Froment, Katie J. Hall, Nick P. Michell, Peter Thatcher, William E. Henley. (2011) Host risk factors and autochthonous hepatitis E infection. European Journal of Gastroenterology & Hepatology 23:12, 1200-1205
CrossRef22
Timothy J. Davern, Naga Chalasani, Robert J. Fontana, Paul H. Hayashi, Petr Protiva, David E. Kleiner, Ronald E. Engle, Hanh Nguyen, Suzanne U. Emerson, Robert H. Purcell, Hans L. Tillmann, Jiezhun Gu, Jose Serrano, Jay H. Hoofnagle. (2011) Acute Hepatitis E Infection Accounts for Some Cases of Suspected Drug-Induced Liver Injury. Gastroenterology 141:5, 1665-1672.e9
CrossRef23
N. Kamar, J. Izopet, L. Rostaing. (2011) No Reactivation of Hepatitis E Virus After Kidney Retransplantation. American Journal of Transplantationno-no
CrossRef24
Philippe Ichai, Didier Samuel. (2011) Epidemiology of liver failure. Clinics and Research in Hepatology and Gastroenterology 35:10, 610-617
CrossRef25
Mohammad Sultan Khuroo. (2011) Discovery of hepatitis E: The epidemic non-A, non-B hepatitis 30 years down the memory lane. Virus Research 161:1, 3-14
CrossRef26
Tatsuo Miyamura. (2011) Hepatitis E virus infection in developed countries. Virus Research 161:1, 40-46
CrossRef27
Michael A. Purdy, Yury E. Khudyakov. (2011) The molecular epidemiology of hepatitis E virus infection. Virus Research 161:1, 31-39
CrossRef28
M. M. Husain, R. Aggarwal, D. Kumar, S. Jameel, S. Naik. (2011) Effector T cells immune reactivity among patients with acute hepatitis E. Journal of Viral Hepatitis 18:10, e603-e608
CrossRef29
Saleem Kamili. (2011) Toward the development of a hepatitis E vaccine. Virus Research 161:1, 93-100
CrossRef30
Krzysztof Krawczynski, Xiang-Jin Meng, Jolanta Rybczynska. (2011) Pathogenetic elements of hepatitis E and animal models of HEV infection. Virus Research 161:1, 78-83
CrossRef31
Mamadou Kaba, Hervé Richet, Isabelle Ravaux, Jacques Moreau, Isabelle Poizot-Martin, Anne Motte, Corinne Nicolino-Brunet, Françoise Dignat-George, Amélie Ménard, Catherine Dhiver, Philippe Brouqui, Philippe Colson. (2011) Hepatitis E virus infection in patients infected with the human immunodeficiency virus. Journal of Medical Virology 83:10, 1704-1716
CrossRef32
Rakesh Aggarwal. (2011) Clinical presentation of hepatitis E. Virus Research 161:1, 15-22
CrossRef33
J. Geng, L. Wang, X. Wang, H. Fu, Q. Bu, P. Liu, Y. Zhu, M. Wang, Y. Sui, H. Zhuang. (2011) Potential risk of zoonotic transmission from young swine to human: seroepidemiological and genetic characterization of hepatitis E virus in human and various animals in Beijing, China. Journal of Viral Hepatitis 18:10, e583-e590
CrossRef34
Jürgen J. Wenzel, Julia Preiß, Mathias Schemmerer, Barbara Huber, Annelie Plentz, Wolfgang Jilg. (2011) Detection of hepatitis E virus (HEV) from porcine livers in Southeastern Germany and high sequence homology to human HEV isolates. Journal of Clinical Virology 52:1, 50-54
CrossRef35
D. Halleux, N. Kanaan, B. Kabamba, I. Thomas, Z. Hassoun. (2011) Hepatitis E virus: an underdiagnosed cause of chronic hepatitis in renal transplant recipients. Transplant Infectious Diseasen/a-n/a
CrossRef36
S. K. Ippagunta, S. Naik, S. Jameel, K. N. S. Ramana, R. Aggarwal. (2011) Viral RNA but no evidence of replication can be detected in the peripheral blood mononuclear cells of hepatitis E virus-infected patients. Journal of Viral Hepatitis 18:9, 668-672
CrossRef37
Stefan G. Hübscher. (2011) What is the long-term outcome of the liver allograft?. Journal of Hepatology 55:3, 702-717
CrossRef38
Nicolas Rose, Aurélie Lunazzi, Virginie Dorenlor, Thiziri Merbah, Florent Eono, Marc Eloit, François Madec, Nicole Pavio. (2011) High prevalence of Hepatitis E virus in French domestic pigs. Comparative Immunology, Microbiology and Infectious Diseases 34:5, 419-427
CrossRef39
S. B. Prabhu, P. Gupta, H. Durgapal, S. Rath, S. D. Gupta, S. K. Acharya, S. K. Panda. (2011) Study of cellular immune response against Hepatitis E Virus (HEV). Journal of Viral Hepatitis 18:8, 587-594
CrossRef40
B. J. WILHELM, A. RAJIĆ, J. GREIG, L. WADDELL, G. TROTTIER, A. HOUDE, J. HARRIS, L. N. BORDEN, C. PRICE. (2011) A systematic review/meta-analysis of primary research investigating swine, pork or pork products as a source of zoonotic hepatitis E virus. Epidemiology and Infection 139:08, 1127-1144
CrossRef41
J. Petrik, J. Coste, C. Fournier-Wirth. (2011) Advances in transfusion medicine in the first decade of the 21st century: Advances in miniaturized technologies. Transfusion and Apheresis Science 45:1, 45-51
CrossRef42
Laurent Alric, Delphine Bonnet, Odile Beynes-Rauzy, Jacques Izopet, Nassim Kamar. (2011) Definitive Clearance of a Chronic Hepatitis E Virus Infection With Ribavirin Treatment. The American Journal of Gastroenterology 106:8, 1562-1563
CrossRef43
FE Keane, M Gompels, RP Bendall, R Drayton, L Jennings, J Black, G Baragwanath, NX Lin, WE Henley, S-L Ngui, S Ijaz, HR Dalton. (2011) Hepatitis E virus coinfection in patients with HIV infection. HIV Medicineno-no
CrossRef44
Anais Vallet-Pichard, Hélène Fontaine, Vincent Mallet, Stanislas Pol. (2011) VIRAL hepatitis in solid organ transplantation other than liver. Journal of Hepatology 55:2, 474-482
CrossRef45
H. Zhang, U. Mohn, J.R. Prickett, S. Schalk, M. Motz, P.G. Halbur, A.R. Feagins, X.J. Meng, T. Opriessnig. (2011) Differences in capabilities of different enzyme immunoassays to detect anti-hepatitis E virus immunoglobulin G in pigs infected experimentally with hepatitis E virus genotype 3 or 4 and in pigs with unknown exposure. Journal of Virological Methods 175:2, 156-162
CrossRef46
Antoine Chaillon, Agnès Sirinelli, Anne De Muret, Elisabeth Nicand, Louis d'Alteroche, Alain Goudeau. (2011) Sustained virologic response with ribavirin in chronic hepatitis E virus infection in heart transplantation. The Journal of Heart and Lung Transplantation 30:7, 841-843
CrossRef47
Raymund R Razonable. (2011) Management of viral infections in solid organ transplant recipients. Expert Review of Anti-infective Therapy 9:6, 685-700
CrossRef48
Ana Isabel González Tallón, Víctor Moreira Vicente, María Luisa Mateos Lindemann, Linette María Achécar Justo. (2011) Hepatitis crónica E en paciente inmunocompetente. Gastroenterología y Hepatología 34:6, 398-400
CrossRef49
Joseph Torresi, Douglas Johnson. (2011) Hepatitis A and E Infection in International Travellers. Current Infectious Disease Reports 13:3, 248-255
CrossRef50
Nassim Kamar, Cyril Garrouste, Elizabeth B. Haagsma, Valérie Garrigue, Sven Pischke, Cécile Chauvet, Jérome Dumortier, Amélie Cannesson, Elisabeth Cassuto–Viguier, Eric Thervet, Filomena Conti, Pascal Lebray, Harry R. Dalton, Robert Santella, Nada Kanaan, Marie Essig, Christiane Mousson, Sylvie Radenne, Anne Marie Roque–Afonso, Jacques Izopet, Lionel Rostaing. (2011) Factors Associated With Chronic Hepatitis in Patients With Hepatitis E Virus Infection Who Have Received Solid Organ Transplants. Gastroenterology 140:5, 1481-1489
CrossRef51
B. Pozzetto, O. Garraud. (2011) Risques viraux émergents en transfusion sanguine. Transfusion Clinique et Biologique 18:2, 174-183
CrossRef52
Anis Khan, Yasuhito Tanaka, Fuat Kurbanov, Abeer Elkady, Zaigham Abbas, Zahid Azam, Amna Subhan, Sajjad Razza, Saeed Hamid, Wasim Jafri, James Shih, Ningshao Xia, Kazuaki Takahashi, Shunji Mishiro, Masashi Mizokami. (2011) Investigating an outbreak of acute viral hepatitis caused by hepatitis E virus variants in Karachi, South Pakistan. Journal of Medical Virology 83:4, 622-629
CrossRef53
M. A. Beale, K. Tettmar, R. Szypulska, R. S. Tedder, S. Ijaz. (2011) Is there evidence of recent hepatitis E virus infection in English and North Welsh blood donors?. Vox Sanguinis 100:3, 340-342
CrossRef54
Nicolas J Mueller, Yasuhiro Takeuchi, Giada Mattiuzzo, Linda Scobie. (2011) Microbial safety in xenotransplantation. Current Opinion in Organ Transplantation 16:2, 201-206
CrossRef55
Ana Isabel González Tallón, Víctor Moreira Vicente, María Luisa Mateos Lindemann. (2011) Hepatitis crónica E. Medicina Clínica
CrossRef56
M. Cornberg, M.P. Manns. (2011) Prävention der Virushepatitis A bis E. Der Internist 52:3, 250-264
CrossRef57
Ratika Srivastava, Rakesh Aggarwal, Sanjeev Sachdeva, Mohammad Intakhab Alam, Shahid Jameel, Sita Naik. (2011) Adaptive immune responses during acute uncomplicated and fulminant hepatitis E. Journal of Gastroenterology and Hepatology 26:2, 306-311
CrossRef58
Alice I Goumba, Xavier Konamna, Narcisse P Komas. (2011) Clinical and epidemiological aspects of a hepatitis E outbreak in Bangui, Central African Republic. BMC Infectious Diseases 11:1, 93
CrossRef59
Julia Benckert, Thomas Berg. (2011) Diagnostik und Klinik der Infektion mit Hepatitis-A- und Hepatitis-E-Viren. Übertragung durch Trinkwasser und Lebensmittel. Pharmazie in unserer Zeit 40:1, 25-29
CrossRef60
Pierre Sellier, Marie-Christine Mazeron, Sophie Tesse, Esma Badsi, John Evans, Jean-Dominique Magnier, Marie-Jose Sanson-Le-Pors, Jean-François Bergmann, Elisabeth Nicand. (2011) Hepatitis E Virus infection in HIV-infected patients with elevated serum transaminases levels. Virology Journal 8:1, 171
CrossRef61
Wikrom Karnsakul, Kathleen B. Schwarz. 2011. Hepatitis. , 800-813.
CrossRef62
Marie-Christine Vantyghem, Philippe Mathurin, Didier Hober, Laurence Bocket, Anne-Sophie Balavoine, Myriam Lazrek, Sébastien Dharancy, Emmanuelle Leteurtre, Julie Kerr-Conte, François Pattou. (2011) Partial graft recovery following eradication of hepatitis E virus infection after successful islet allograft transplantation. Transplant International 24:1, e13-e15
CrossRef63
Romil Saxena, Swan N. Thung. 2011. Pathology of Liver Transplantation. , 599-630.
CrossRef64
Amit Goel, Rakesh Aggarwal. (2011) Prevention of hepatitis E: another step forward. Future Microbiology 6:1, 23-27
CrossRef65
Rakesh Aggarwal. (2011) Hepatitis E: Historical, contemporary and future perspectives. Journal of Gastroenterology and Hepatology 26, 72-82
CrossRef66
Janick Selves, Nassim Kamar, Jean-Michel Mansuy, Jean-Marie Péron. (2010) Les hépatites virales E : une maladie émergente en France. Annales de Pathologie 30:6, 432-438
CrossRef67
Jeff Turner, Andrew Godkin, Peter Neville, Jerry Kingham, Chin Lye Ch'ng. (2010) Clinical characteristics of hepatitis E in a “Non-Endemic” population. Journal of Medical Virology 82:11, 1899-1902
CrossRef68
Nassim Kamar, Lionel Rostaing, Florence Abravanel, Cyril Garrouste, Sebastien Lhomme, Laure Esposito, Grégoire Basse, Olivier Cointault, David Ribes, Marie Béatrice Nogier, Laurent Alric, Jean Marie Peron, Jacques Izopet. (2010) Ribavirin Therapy Inhibits Viral Replication on Patients With Chronic Hepatitis E Virus Infection. Gastroenterology 139:5, 1612-1618
CrossRef69
T.S. Min, H.J. Han, S.H. Park. (2010) Porcine Xenotransplantation to Primates. Asian-Australasian Journal of Animal Sciences 23:11, 1535-1542
CrossRef70
Rosario Vivek, Lalit Nihal, Jeyaram Illiayaraja, Pawan K. Reddy, Rajiv Sarkar, C. E. Eapen, Gagandeep Kang. (2010) Investigation of an epidemic of Hepatitis E in Nellore in south India. Tropical Medicine & International Health 15:11, 1333-1339
CrossRef71
Nicole Pavio, Xiang-Jin Meng, Christophe Renou. (2010) Zoonotic hepatitis E: animal reservoirs and emerging risks. Veterinary Research 41:6, 46
CrossRef72
Suzanne Tavitian, Jean-Marie Péron, Anne Huynh, Jean-Michel Mansuy, Loic Ysebaert, Françoise Huguet, Jean-Pierre Vinel, Michel Attal, Jacques Izopet, Christian Récher. (2010) Hepatitis E virus excretion can be prolonged in patients with hematological malignancies. Journal of Clinical Virology 49:2, 141-144
CrossRef73
Nicole Pavio, Jean-Michel Mansuy. (2010) Hepatitis E in high-income countries. Current Opinion in Infectious Diseases 23:5, 521-527
CrossRef74
Juan F. Gallegos-Orozco, Jorge Rakela. 2010. Acute Viral Hepatitis: Hepatitis A, Hepatitis E, and Other Viruses. , 173-185.
CrossRef75
N. Kamar, F. Abravanel, C. Garrouste, I. Cardeau-Desangles, J. M. Mansuy, H. Weclawiak, J. Izopet, L. Rostaing. (2010) Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. Nephrology Dialysis Transplantation 25:8, 2792-2795
CrossRef76
S. Pischke, H. Ho, F. Urbanek, D. Meyer-Olsen, P. V. Suneetha, M. P. Manns, M. Stoll, H. Wedemeyer. (2010) Hepatitis E in HIV-positive patients in a low-endemic country. Journal of Viral Hepatitis 17:8, 598-599
CrossRef77
William Bernal, Georg Auzinger, Anil Dhawan, Julia Wendon. (2010) Acute liver failure. The Lancet 376:9736, 190-201
CrossRef78
Christophe Renou, Alain Lafeuillade, Jean-François Cadranel, Nicole Pavio, Alexandre Pariente, Thierry Allègre, Cécile Poggi, Guillaume Pénaranda, François Cordier, Elisabeth Nicand. (2010) Hepatitis E virus in HIV-infected patients. AIDS 24:10, 1493-1499
CrossRef79
E. Fourquet, J.M. Mansuy, C. Bureau, C. Recher, J.P. Vinel, J. Izopet, J.M. Péron. (2010) Severe thrombocytopenia associated with acute autochthonous hepatitis E. Journal of Clinical Virology 48:1, 73-74
CrossRef80
F. Bihl, F. Negro. (2010) Hepatitis E virus: a zoonosis adapting to humans. Journal of Antimicrobial Chemotherapy 65:5, 817-821
CrossRef81
N. Kamar, J. Izopet, P. Cintas, C. Garrouste, E. Uro-Coste, O. Cointault, L. Rostaing. (2010) Hepatitis E Virus-Induced Neurological Symptoms in a Kidney-Transplant Patient with Chronic Hepatitis. American Journal of Transplantation 10:5, 1321-1324
CrossRef82
Stephan Vetter, Dirk Hartmann, Ralf Jakobs, Jürgen F. Riemann. (2010) Seltene akute Hepatitis bei einer Hämochromatosepatientin: eine Zoonose?. Medizinische Klinik 105:4, 305-309
CrossRef83
X. J. Meng. (2010) Recent advances in Hepatitis E Virus. Journal of Viral Hepatitis 17:3, 153-161
CrossRef84
H. C. LEWIS, O. WICHMANN, E. DUIZER. (2010) Transmission routes and risk factors for autochthonous hepatitis E virus infection in Europe: a systematic review. Epidemiology and Infection 138:02, 145
CrossRef85
Nassim Kamar, Florence Abravanel, Janick Selves, Cyril Garrouste, Laure Esposito, Laurence Lavayssière, Olivier Cointault, David Ribes, Isabelle Cardeau, Marie Béatrice Nogier, Jean Michel Mansuy, Fabrice Muscari, Jean Marie Peron, Jacques Izopet, Lionel Rostaing. (2010) Influence of Immunosuppressive Therapy on the Natural History of Genotype 3 Hepatitis-E Virus Infection After Organ Transplantation. Transplantation 89:3, 353-360
CrossRef86
H. R. DALTON, R. P. BENDALL, C. PRITCHARD, W. HENLEY, D. MELZER. (2010) National mortality rates from chronic liver disease and consumption of alcohol and pig meat. Epidemiology and Infection 138:02, 174
CrossRef87
S. Brost, J.J. Wenzel, T.M. Ganten, M. Filser, C. Flechtenmacher, S. Boehm, A. Astani, W. Jilg, M. Zeier, P. Schnitzler. (2010) Sporadic cases of acute autochthonous hepatitis E virus infection in Southwest Germany. Journal of Clinical Virology 47:1, 89-92
CrossRef88
Sven Pischke, Pothakamuri V. Suneetha, Christine Baechlein, Hannelore Barg-Hock, Albert Heim, Nassim Kamar, Jerome Schlue, Christian P. Strassburg, Frank Lehner, Regina Raupach, Birgit Bremer, Peter Magerstedt, Markus Cornberg, Frauke Seehusen, Wolfgang Baumgaertner, Juergen Klempnauer, Jacques Izopet, Michael P. Manns, B. Grummer, Heiner Wedemeyer. (2010) Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transplantation 16:1, 74-82
CrossRef89
Anne Laure Millard, Nicolas J. Mueller. (2010) Can human viruses infect porcine xenografts?. Xenotransplantation 17:1, 6-10
CrossRef90
Mamadou Kaba, Philippe Colson, Jean-Pierre Musongela, Léon Tshilolo, Bernard Davoust. (2010) Detection of hepatitis E virus of genotype 3 in a farm pig in Kinshasa (Democratic Republic of the Congo). Infection, Genetics and Evolution 10:1, 154-157
CrossRef91
Maria Buti, Cecilia Cabrera, Rosendo Jardi, Luis Castells, Rafael Esteban. (2010) Are recipients of solid organ transplantation a high-risk population for hepatitis E virus infection?. Liver Transplantation 16:1, 106-107
CrossRef92
Mariana Ghinoiu, Sylvie Naveau, Nadège Barri-Ova, Juliette Thaury, Liliane Grangeot-Keros, Gabriel Perlemuter. (2009) Acute hepatitis E infection associated with a false-positive serology against Epstein–Barr virus. European Journal of Gastroenterology & Hepatology 21:12, 1433-1435
CrossRef93
A. Madejón, E. Vispo, M. Bottecchia, M. Sánchez-Carrillo, J. García-Samaniego, V. Soriano. (2009) Lack of hepatitis E virus infection in HIV patients with advanced immunodeficiency or idiopathic liver enzyme elevations. Journal of Viral Hepatitis 16:12, 895-896
CrossRef94
Mamadou Kaba, Bernard Davoust, Jean-Lou Marié, Marc Barthet, Mireille Henry, Catherine Tamalet, Didier Raoult, Philippe Colson. (2009) Frequent transmission of hepatitis E virus among piglets in farms in Southern France. Journal of Medical Virology 81:10, 1750-1759
CrossRef95
Elizabeth B. Haagsma, Hubert G. M. Niesters, Arie P. van den Berg, Annelies Riezebos-Brilman, Robert J. Porte, Harry Vennema, Johan H. J. Reimerink, Marion P. G. Koopmans. (2009) Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transplantation 15:10, 1225-1228
CrossRef96
M. Fogeda, A. Avellón, C.G. Cilla, J.M. Echevarría. (2009) Imported and autochthonous hepatitis E virus strains in Spain. Journal of Medical Virology 81:10, 1743-1749
CrossRef97
Dalton, Harry R., Bendall, Richard P., Keane, Frances E., , Tedder, Richard S., Ijaz, Samreen, . (2009) Persistent Carriage of Hepatitis E Virus in Patients with HIV Infection. New England Journal of Medicine 361:10, 1025-1027
Full Text98
Rakesh Aggarwal, Sita Naik. (2009) Epidemiology of hepatitis E: Current status. Journal of Gastroenterology and Hepatology 24:9, 1484-1493
CrossRef99
George Mells, Caroline Mann, Stefan Hubscher, James Neuberger. (2009) Late protocol liver biopsies in the liver allograft: A neglected investigation?. Liver Transplantation 15:8, 931-938
CrossRef100
Philippe Colson, Mamadou Kaba, Jacques Moreau, Philippe Brouqui. (2009) Hepatitis E in an HIV-infected patient. Journal of Clinical Virology 45:4, 269-271
CrossRef101
Victoria Johnston, Jane M. Stockley, David Dockrell, David Warrell, Robin Bailey, Geoffrey Pasvol, John Klein, Andrew Ustianowski, Michael Jones, Nicholas J. Beeching, Michael Brown, Ann L.N. Chapman, Frances Sanderson, Christopher J.M. Whitty. (2009) Fever in returned travellers presenting in the United Kingdom: Recommendations for investigation and initial management. Journal of Infection 59:1, 1-18
CrossRef102
M. S. Khuroo, S. Kamili, M. S. Khuroo. (2009) Clinical course and duration of viremia in vertically transmitted hepatitis E virus (HEV) infection in babies born to HEV-infected mothers. Journal of Viral Hepatitis 16:7, 519-523
CrossRef103
S. Schaefer. (2009) Sexuell übertragbare Hepatitisviren. Der Hautarzt 60:6, 456-464
CrossRef104
Bulent Degertekin, Anna SF Lok. (2009) Update on viral hepatitis: 2008. Current Opinion in Gastroenterology 25:3, 180-185
CrossRef105
Linda Scobie, Yasuhiro Takeuchi. (2009) Porcine endogenous retrovirus and other viruses in xenotransplantation. Current Opinion in Organ Transplantation 14:2, 175-179
CrossRef106
Jay H. Lefkowitch. (2009) Recent developments in liver pathology. Human Pathology 40:4, 445-455
CrossRef107
C. Rigamonti, M. Vidali, M. F. Donato, S. Sutti, G. Occhino, A. Ivaldi, E. Arosio, F. Agnelli, G. Rossi, M. Colombo, E. Albano. (2009) Serum Autoantibodies Against Cytochrome P450 2E1 (CYP2E1) Predict Severity of Necroinflammation of Recurrent Hepatitis C. American Journal of Transplantation 9:3, 601-609
CrossRef108
Samad Amini-Bavil-Olyaee, Christian Trautwein, Frank Tacke. (2009) Hepatitis E vaccine: current status and future prospects. Future Virology 4:2, 143-154
CrossRef109
René Gérolami, Valérie Moal, Christophe Picard, Philippe Colson. (2009) Hepatitis E virus as an emerging cause of chronic liver disease in organ transplant recipients. Journal of Hepatology 50:3, 622-624
CrossRef110
Mami Yoshitomi, Takaaki Koshiba, Hironori Haga, Ying Li, Xiangdong Zhao, Donghua Cheng, Aya Miyagawa, Hiromi Sakashita, Tatsuaki Tsuruyama, Hidenori Ohe, Mikiko Ueda, Shinya Okamoto, Hiroto Egawa, Kathryn Wood, Shimon Sakaguchi, Toshiaki Manabe, Koichi Tanaka, Shinji Uemoto. (2009) Requirement of Protocol Biopsy Before and After Complete Cessation of Immunosuppression After Liver Transplantation. Transplantation 87:4, 606-614
CrossRef111
Florian Bihl, Francesco Negro. (2009) Chronic hepatitis E in the immunosuppressed: A new source of trouble?. Journal of Hepatology 50:2, 435-437
CrossRef112
J.M. Mansuy, F. Abravanel, M. Miedouge, C. Mengelle, C. Merviel, M. Dubois, N. Kamar, L. Rostaing, L. Alric, J. Moreau, J.M. Peron, J. Izopet. (2009) Acute hepatitis E in south-west France over a 5-year period. Journal of Clinical Virology 44:1, 74-77
CrossRef113
Ole Wichmann, Sven Schimanski, Judith Koch, Martin Kohler, Camilla Rothe, Annelie Plentz, Wolfgang Jilg, Klaus Stark. (2008) Phylogenetic and Case‐Control Study on Hepatitis E Virus Infection in Germany. The Journal of Infectious Diseases 198:12, 1732-1741
CrossRef114
P. Colson, C. Dhiver, R. Gérolami. (2008) Hepatitis E virus as a newly identified cause of acute viral hepatitis during human immunodeficiency virus infection. Clinical Microbiology and Infection 14:12, 1176-1180
CrossRef115
Vivek Chandra, Shikha Taneja, Manjula Kalia, Shahid Jameel. (2008) Molecular biology and pathogenesis of hepatitis E virus. Journal of Biosciences 33:4, 451-464
CrossRef116
Harry R Dalton, Richard Bendall, Samreen Ijaz, Malcolm Banks. (2008) Hepatitis E: an emerging infection in developed countries. The Lancet Infectious Diseases 8:11, 698-709
CrossRef117
Peer B. Christensen, Ronald E. Engle, Charlotte Hjort, Keld M. Homburg, Werner Vach, Jørgen Georgsen, Robert H. Purcell. (2008) Time Trend of the Prevalence of Hepatitis E Antibodies among Farmers and Blood Donors: A Potential Zoonosis in Denmark. Clinical Infectious Diseases 47:8, 1026-1031
CrossRef118
Mohammad S Khuroo, Mehnaaz S Khuroo. (2008) Hepatitis E virus. Current Opinion in Infectious Diseases 21:5, 539-543
CrossRef119
Udayakumar Navaneethan, Mayar Al Mohajer, Mohamed T. Shata. (2008) Hepatitis E and pregnancy: understanding the pathogenesis. Liver International 28:9, 1190-1199
CrossRef120
Rakesh Aggarwal, Kris Kowdley, Geoffrey McCaughan, Christian Trautwein. (2008) Hepatitis E: Does it cause chronic hepatitis?. Hepatology 48:4, 1328-1330
CrossRef121
Philippe Ichai, Didier Samuel. (2008) Etiology and prognosis of fulminant hepatitis in adults. Liver Transplantation 14:S2, S67-S79
CrossRef122
Masaharu Takahashi, Kentaro Yamada, Yu Hoshino, Hideyuki Takahashi, Koji Ichiyama, Toshinori Tanaka, Hiroaki Okamoto. (2008) Monoclonal antibodies raised against the ORF3 protein of hepatitis E virus (HEV) can capture HEV particles in culture supernatant and serum but not those in feces. Archives of Virology 153:9, 1703-1713
CrossRef123
Monique I Andersson, Jon Hughes, Fiona H Gordon, Samreen Ijaz, Matthew Donati. (2008) Of pigs and pregnancy. The Lancet 372:9644, 1192
CrossRef124
N. Kamar, J.-M. Mansuy, O. Cointault, J. Selves, F. Abravanel, M. Danjoux, P. Otal, L. Esposito, D. Durand, J. Izopet, L. Rostaing. (2008) Hepatitis E Virus-Related Cirrhosis in Kidney-and Kidney-Pancreas-Transplant Recipients. American Journal of Transplantation 8:8, 1744-1748
CrossRef125
(2008) Chronic Hepatitis E and Organ Transplants. New England Journal of Medicine 358:23, 2521-2522
Full Text126
Tai-Nin Chau. (2008) Hepatitis E: A potential vaccine-preventable disease needs global concern. Journal of Gastroenterology and Hepatology 23:6, 827-828
CrossRef127
(2008) Hepatitis E in kidney transplant recipients. Nature Clinical Practice Gastroenterology & Hepatology 5:6, 295-295
CrossRef128
Gérolami, René, Moal, Valérie, , Colson, Philippe, . (2008) Chronic Hepatitis E with Cirrhosis in a Kidney-Transplant Recipient. New England Journal of Medicine 358:8, 859-860
Full Text
- Letters
